CJC-1295 with DAC: Comprehensive Analysis

How does the Drug Affinity Complex modification extend the half-life of this GHRH analog? CJC-1295 with DAC represents the long-acting version of CJC-1295 with albumin-binding properties for sustained GH release.

As GHRH research specialists, we’ve analyzed CJC-1295 DAC pharmacology from DAC mechanism to clinical applications and comparison with non-DAC version.

What is CJC-1295 with DAC?

CJC-1295 with DAC is a modified GHRH analog incorporating a Drug Affinity Complex that enables albumin binding for dramatically extended half-life and sustained growth hormone release

Developed through peptide modification technology to create long-acting GHRH analogs. The DAC modification enables albumin binding, extending half-life from minutes to days.

Key Characteristics

• Classification: Long-acting GHRH analog/research compound

• Primary Mechanism: Sustained GHRH receptor activation with prolonged GH elevation

• Key Benefits: Less frequent dosing, sustained GH and IGF-1 elevation

• Research Status: Research compound with extensive study in GH-related applications

Mechanism of Action

CJC-1295 with DAC provides sustained GHRH receptor stimulation

How CJC-1295 with DAC Works

• Primary Action: DAC modification enables covalent binding to serum albumin

• Secondary Effects: Albumin binding protects from degradation and extends half-life

• Downstream Impact: Sustained GHRH receptor activation promotes continuous GH release

• Physiological Outcome: Elevated GH leads to increased IGF-1 production

Comparison with Peptide Therapies

Understanding CJC-1295 with and without DAC

CJC-1295 with DAC vs Related Peptides

FactorCJC-1295 with DACCJC-1295 no DACSermorelin MechanismSustained GHRH receptor activation via albumin bindingPulsatile GHRH stimulation, shorter half-lifeNatural GHRH analog, short half-life BenefitsOnce-weekly dosing, sustained GH elevationMore physiological pulsatile releaseFDA history, established safety AdministrationWeekly subcutaneous injectionDaily or twice-daily injectionDaily injection Research LevelResearch compound, extensive dataResearch compound, well-characterizedPrevious FDA approval for diagnostics

Research Evidence

Research supports efficacy of CJC-1295 with DAC

Key Research Findings

• Phase I/II Clinical Trial: Sustained IGF-1 elevation for 6-8 days after single dose

• PK/PD Studies: Half-life extended to 6-8 days vs minutes for unmodified GHRH

• Body Composition Studies: Increased lean mass and decreased fat mass in research subjects

Potential Applications

CJC-1295 with DAC is researched for multiple applications

Research Applications

• Age-related GH decline

• Body composition optimization

• Recovery and regeneration support

Safety Considerations

Safety considerations for CJC-1295 with DAC

• Injection site reactions most common

• Sustained GH elevation may have different effects than pulsatile

• Long-term safety data continues to accumulate

Conclusion

CJC-1295 with DAC represents a long-acting approach to GHRH therapy

Optimization of DAC technology for other peptide applications